(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 12.51% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.76%.
Biodesix's revenue in 2026 is $105,212,000.On average, 9 Wall Street analysts forecast BDSX's revenue for 2026 to be $1,213,083,103, with the lowest BDSX revenue forecast at $1,097,540,819, and the highest BDSX revenue forecast at $1,305,228,630. On average, 9 Wall Street analysts forecast BDSX's revenue for 2027 to be $1,492,624,466, with the lowest BDSX revenue forecast at $1,322,526,707, and the highest BDSX revenue forecast at $1,641,654,054.
In 2028, BDSX is forecast to generate $1,718,053,894 in revenue, with the lowest revenue forecast at $1,583,328,486 and the highest revenue forecast at $1,816,298,102.